You are here : Home » Lakeland Regional Cancer Center » Research and Clinical Trials » Renal Cell (Kidney) Cancer
Print Page
Renal Cell (Kidney) Cancer
Clinical Trial #S0931:
-
Everolimus versus placebo as a way to reduce risk of recurrence for patients who have had a kidney cancer surgically removed.
-
Participants may have either a clear cell or non clear cell renal cancer. Bilateral tumors are allowed if they were resected. The participation in this study must start within 84 days of surgery.
-
Exclusions include, but are not limited to: Prior anti cancer therapy, live vaccine within 7 days, uncontrolled pulmonary disease, severe cardiac disease, cirrhosis or severe liver impairment, HIV and malabsorption syndrome.
